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JAK-STAT signaling through the JAK2V617F mutation is central to the pathogenesis of myeloproliferative neoplasms
(MPN). However, other events could precede the JAK2 mutation. The aim of this study is to analyze the phenotypic
divergence between polycytemia vera (PV) and essential thrombocytemia (ET) to find novel therapeutics targets by
a proteomic and functional approach to identify alternative routes to JAK2 activation. Through 2D-DIGE and mass
spectrometry of granulocyte protein from 20 MPN samples, showed differential expression of HSP70 in PV and ET
besides other 60 proteins. Immunohistochemistry of 46 MPN bone marrow samples confirmed HSP70 expression.
The median of positive granulocytes was 80% in PV (SD 35%) vs. 23% in ET (SD 34.25%). In an ex vivo model KNK437
was used as an inhibition model assay of HSP70, showed dose-dependent inhibition of cell growth and burst
formation unit erythroid (BFU-E) in PV and ET, increased apoptosis in the erythroid lineage, and decreased pJAK2
signaling, as well as a specific siRNA for HSP70. These data suggest a key role for HSP70 in proliferation and survival
of the erythroid lineage in PV, and may represent a potential therapeutic target in MPN, especially in PV.
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Myeloproliferative neoplasms (MPNs) BCR-ABL negative
are clonal, stem cell diseases. Although JAK2 kinase
(JAK2V617F) is the most frequent mutation it is not the pri-
mary molecular event in this group of diseases and several
other mutations are described [1-4]. In general these mu-
tations produce an increase in signaling pathways down-
stream of JAK2. For example, STAT3/5 [5-7] is a central
event in the pathogenesis of polycythemia vera (PV).
Current treatments only control the symptoms of the dis-
ease and do not offer the possibility of a clinical/molecular
remission or cure [8,9]. JAK2 inhibitors are emerging as
promising new treatments in this disease. However, they
do not seem to achieve complete molecular or clinical
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reproduction in any medium, provided the orProteomic screening methods to find new physiopatho-
genic candidate proteins have not been widely employed
in cancer, although a large number of molecular genetic
tests have been performed with variable results. One such
proteomic method is two-dimensional difference gel elec-
trophoresis (2D-DIGE), which assesses the protein profile
in an accessible, economical, and high-resolution manner.
However, several studies show that the resolution power
of 2D-DIGE decreases when the cellular type or the
amount and quality of the protein samples are not selected
properly [12].
Molecular chaperones are essential for stabilizing the
fragile structures of many receptors, protein kinases, and
transcription factors that participate in the pathways of
normal cellular growth. Heat shock proteins (HSP) are re-
quired to maintain signaling proteins in an active con-
formation that can be rapidly triggered by growth signals.
Thus, HSP may be viewed as facilitators of real-time
responses to extracellular signals, particularly in develop-
ment and cell renewal. Recently, the chaperone HSP90 has
been implicated in protection of JAK2 from degradation inl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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proposed as an alternative treatment to JAK2 inhibitors
[13]. Heat shock protein 70 (HSP70) is related to HSP90
and blocks the apoptotic pathway at different levels [14,15].
HSP70 reduces caspase activation (mainly caspase-3) and
suppresses mitochondrial damage and nuclear fragmenta-
tion. One of the final targets of caspase-3 is the transcrip-
tion factor GATA-1 [16,17].
Overexpression of HSP70 can provide a selective survival
advantage to tumor cells in part due to its ability to inhibit
multiple pathways of cell death, including both intrinsic
and extrinsic apoptosis. With regard to the intrinsic apop-
tosis pathway, HSP70 can bind directly to the pro-
apoptotic BCL2 family member BAX and prevent it from
translocating to mitochondria, where the latter disrupts
mitochondrial membranes following an apoptotic stimulus.
Additionally, interaction with HSP70 prevents the recruit-
ment of APAF-1 and procaspase-9 to the apoptosome.
Additionally, HSP70 modulates proliferative pathways
via MAPK; it modulates JNK and, RAF-1 and ERK phos-
phorylation [18-20] HSP70 and HSP90 share the ability to
inhibit APAF-1 to block the apoptosis cascade, [21] and it
is tempting to speculate a major role of HSP70 and HSP90
in the apoptotic resistance of MPN. These proteins may
work separately or together as a HSP90-HOP-HSP70 com-
plex [22,23]. The aim of the present study was to analyzeTraining Set
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Figure 1 Flow chart describing the three-steps to proteomic screenin
and essential thrombocythemia (ET). The training set includes two-dimen
(MS); the protein validation set includes immunohistochemistry (IHC); and the
and stem cells studies.the phenotypic divergence between PV and ET using
proteomic screening, with the goal to identify additionally
routes to JAK2 inhibitors for targeted therapy. We identi-
fied 65 differentially expressed proteins, with HSP70 the
most significantly enhanced. HSP70 differential expression
was validated by protein expression analysis and an ex vivo
model of MPN.
Materials and methods
Patients
Sixty-seven patients diagnosed with MPN (28 PV, 25 ET
JAK2V617F, and 14 ET JAK2WT) were included in this study,
in addition to 26 healthy donors. A diagnosis of MPN was
based on the World Health Organization criteria 2001/
2008, or the Polycythemia Vera Southern Study Group (ac-
cording to the standard criteria at the moment of diagno-
sis). Mutational Screening for JAK2 V617F was performed
using real time PCR on DNA from whole peripheral blood.
The study was approved by the 12 Octubre Hospital eth-
ics committee and written informed consent was obtained
from all patients, according to the Declaration of Helsinki.
A flow diagram of the patients is shown in Figure 1.
Sample collection and preparation
Peripheral venous blood was collected in ethylenedia-
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functional validation set includes burst formation unit-erythroid (BFU-E)
Table 1 Clinical and laboratory features of
myeloproliferative neoplasm (MPN) patients used for
two-dimensional difference gel electrophoresis (2D-DIGE)
and mass spectrometry (MS) assays
Clinical and laboratory variables PV ET
Patients 10 10
Gender (M/F) 5/5 3/7
Age at diagnosisa 68 (60–84) 38 (34–56)
Splenomegaly at diagnosis 0/10 1/10
Hepatomegaly at diagnosis 0/10 1/10
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cells were isolated by Ficoll-Paque density gradient centri-
fugation (Pharmacia, Freiburg, Germany). Erythrocytes
were eliminated using a commercial red blood cell lysis
buffer (Roche Applied Sciences, Manheim, Germany),
with more than 90% granulocytes. Lymphocyte contamin-
ation was assessed in five samples by flow cytometry, and
was less than 2% of the total cell count.
Protein cytosolic fractions of granulocytes were ex-
tracted using Proteoextract subcellular proteome extrac-
tion (Calbiochem, Darmstaz, Germany).Hemoglobin (g/100 mL) at diagnosisa 18.3 (17.4-20.3) 14.95 (12.6-16.9)
Hematocrit at diagnosisa 58.25 (51–62.5) 45,52 (37.4-49,7)
WBC (x109/L) at diagnosisa 10.65 (3.94-16.15) 12.1 (8.1-14.5)
Platelets (x109/L) at diagnosisa 371 (168–394) 615.5 (564–657)
Increased LDH at diagnosis 3/10 1/10
Thrombotic events at diagnosis 1/10 0/10Determining total protein content
To ensure equal protein loading on both 2D-PAGE and,
the protein concentration was determined using a non-
interfering assay (RC-DC Protein Assay Kit; BIO-RAD,
NY, USA).Hemorrhagic events at diagnosis 0/10 0/10
Thrombotic events after diagnosis 1/10 0/10
Hemorrhagic events after diagnosis 0/10 0/10
Response to treatment 3/6 1/10
Disease duration (in months) 55.5 (14–179) 92.5 (13–100)
Treatment duration (in months)a 7 (0–179) 0 (0–86)
PV, polycythemia vera; ET, essential thrombocythemia; HU, hydroxyurea; M,
male; F, female; WBC, white blood cells, LDH, lactate dehydrogenase; aMedian
value (range) is reported.Two-dimensional difference gel electrophoresis
Protein cytosolic fractions from peripheral blood granu-
locytes from 10 ET, 10 PV, and 10 healthy donors as
controls, were initially pooled for two-dimensional dif-
ference gel electrophoresis (2D-DIGE). We performed
three analysis, ET versus PV pools, ET versus control
pools, and PV versus control pools by duplicate (6 gels),
changing labels with different dye (Cy3 or Cy5), for each
pool in each analysis. Patients and clinical data of the
2D-DIGE study are presented in Table 1.
The PV and ET cytosolic protein pools (20 micrograms
each) were minimally labeled with 160 pmol of the N-
hydroxysuccinimide esters of Cy3 or Cy5 fluorescent cya-
nine dyes (GE Healthcare, Piscataway, NJ, USA). An
internal standard pool was generated by mixing equal
amounts of proteins obtained from all the samples and la-
beled with 160 pmol of Cy2 dye. PV and ET labeled protein
pools and the internal standard protein samples, were
combined in pairs, diluted In rehydration buffer (7 M urea,
2 M thiourea, 4% CHAPS, 10 mM DTT, 0.5% carrier
ampholites pH 3–11 NL), and applied by cup loading to
18 cm IPG strips pH 3–11 NL (GE Healthcare, Piscataway,
NJ, USA), previously rehydrated with 340 μl of rehydration
buffer containing 1.2% DeStreak. The first dimension was
run at 0.05 mA/IPG strip in an IPGphor IEF System (GE
Healthcare, Piscataway, NJ, USA) following a voltage in-
crease until 43000 Vhrs were reached. Strips were then
reduced and alkylated in the dark in SDS equilibration buf-
fer (75 mM Tris pH 8,8, 6 M urea, 30% (v/v) glycerol, 2%
(w/v) SDS, and traces of bromophenol blue) containing 1%
(w/v) DTT or 4% (w/v) iodoacetamide. Finally, the pro-
teins were separated using 12.5% tris-glycine gels in an
Ettan Dalt Six device (GE Healthcare, Piscataway, NJ,
USA) at 20°C.Image acquisition and statistical analysis
Following electrophoresis, the 2D-gels were scanned in
a Typhoon 9400 scanner (GE Healthcare, Piscataway,
NJ, USA) at 100 μm resolution, and with the appropri-
ate wavelengths and filters for Cy2, Cy3 and Cy5 dyes.
Relative protein quantification was performed using
DeCyder software v7.0. Background subtraction, quanti-
fication, and normalization were automatically applied
with low experimental variation. Differences were calcu-
lated as average ratios for each spot, and average ratios >
or = 1.5 or < or = −1.5. The student’s t-test was used to
compare average ratios for each spot between PV and ET
samples. P values less than 0.05 were considered signifi-
cant. Individual coordinates corresponding to the spots of
interest were automatically calculated and automatic spot
pick-up was carried out using a Spot Picking Robot (GE
Healthcare, Piscataway, NJ, USA).
Protein identification by mass spectrometry
In-gel protein digestion and sample preparation
Spots of interest were excised from gels, deposited in 96-
well plates and processed automatically in a Proteineer DP
(Bruker Daltonics, Bremen, Germany). The digestion proto-
col used was based on that of Schevchenko et al. with
minor variations [24]. Modified porcine trypsin (sequencing
grade; Promega, Madison, WI) was added at a final
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bicarbonate solution and gels were digested at 37°C for 6 h.
The reaction was stopped by adding 0.5% TFA for peptide
extraction. Tryptic peptides were dried by speed-vacuum
centrifugation and resuspended in 4 μl for MALDI TOF/
TOF analysis.
MALDI peptide mass fingerprinting, MS/MS analysis and
database searching
For MALDI-TOF/TOF analysis, samples were automatic-
ally acquired in an ABi 4800 MALDI TOF/TOF mass
spectrometer (AB Sciex, Framingham, MA, USA) in posi-
tive ion reflector mode (ion acceleration voltage was 25 kV
for MS acquisition and 1 kV for MSMS). PMF and MSMS
fragment ion spectra were smoothed, corrected to zero
baseline and internally calibrated with the mass signals of
trypsin autolysis ions to reach a typical mass measurement
accuracy of < 25 ppm. Known trypsin and keratin mass sig-
nals, as well as potential sodium and potassium adducts
(+21 Da and +39 Da) were removed from the peak list. To
submit the combined PMF and MS/MS data to MASCOT
software v.2.1 (Matrix Science, London, UK), GPS Explorer
v4.9 was used, searching in the non-redundant UniProt/
SwissProt protein database (taxonomy: Homo sapiens).
Immunohistochemistry
Twelve PV, 10 ET JAK2 positive, 13 ET JAK2 negative and
11 controls from formalin fixed and paraffin-embedded
bone marrow biopsies were collected. Non haematological
diseases patients or patients with secondary thrombocyto-
sis and/or erythrocytosis, both with free-infiltrate bone
marrow were used as negative MPN controls. They were
used to validate the DIGE/MS results. Patients and clinical
data of the IHC study are presented in Table 2.
We performed immunohistochemical (IHC) staining in
four micron-thick tissue sections from all cohorts for
HSP70 (clone MAB1663 anti-h/m/r/rHSP70, 1/8000 dilu-
tion; R&D, Minneapolis, MN, USA), SERPINB1 (clone
HPA018871 anti-SERPINB1, 1/12000 dilution, SIGMA,
Steinheim, Germany), and LTA4H (clone HPA00399 anti-
LTA4H, 1/50 dilution, SIGMA, Steinheim, Germany).
After incubation, immunodetection was done with the
DAKO EnVision visualization method (Dako, Glostrup,
Denmark), with diaminobenzidine chromogen as the sub-
strate. Sections were counter stained with hematoxylin.
Immunostaining was evaluated by two different patho-
logists, using granulocyte percent and stain intensity cri-
teria. Only distinct and intense cytoplasmic staining was
considered positive.
Burst formation unit-erythroid culture colony assay
Colony assays were performed using Methocult TM GF_
H4535 (StemCell Technologies, Vancouver, BC, Canada,
http://www.stemcell.com).In brief, a 0.5 mL cell suspension, containing 5×105
peripheral blood mononuclear cells from four PV and
four ET patients, and three healthy donors as controls,
were each mixed in 500 μl of methylcellulose solution
consisting of methocult, 20 ng/mL interleukin 3 (IL-3),
and 50 ng/mL stem-cell factor (SCF) and 3 U/mL
erythropoietin (all fromStemCell Technologies, Vancouver,
BC, Canada) in 3.5-cm culture dishes. We cultured the
cells with (3 U/mL erythropoietin) and without EPO (en-
dogenous growth).
Additionally, the burst formation unit-erythroid (BFU-E)
assay was performed with 2×103 CD34+ bone marrow cells
per well from two PV, two ET, and two cord blood samples
as controls.
HSP70 was inhibited by 100 μM, 50 μM, and 10 μM
KNK437 (Calbiochem, Darmstadt, Germany). For experi-
mental controls we excluded KNK437, and all samples
were assayed in duplicate. After 2 weeks, the colonies were
counted. Colony morphology was also observed using an
inverted light microscope.
Cells from the BFU-E were extracted, washed and resus-
pended in 10 mL PBS. Ten microlitres aliquots of cells
were used to test viability using trypan blue (1:1). Cells
were analyzed by flow cytometry after the addition of
10 μl (5 μl of APC antibodies) of markers; CD71-FITC,
CD45-PerCP, CD44-PE, annexin V-APC, CD41a-FITC,
and CD34-APC (BD Biosciences Europe, Oxford, UK), in-
cubated for 30 minutes at 4°C, and washed with PBS or
binding buffer 1X (BD Biosciences Europe, Oxford, UK)
(in the case of annexin) before analysis. Samples were
analyzed using a flow cytometer FACSCalibur (Beckman
Coulter, Fullerton, CA). Cell suspensions with IgG iso-
type control antibodies (BD Biosciences Europe, Oxford,
UK) were used as negative controls.
DNA from BFU-E cultured cells was extracted using the
Maxwell 16 SEV automated extraction system (Promega,
Manheim, Germany).
Protein from cells was extracted with the CBA extraction
kit (BD Biosciences Europe, Oxford, UK) according to the
manufacturer’s instructions but with the addition of phos-
phatase and protease inhibitors. CBA technology is a set of
microspheres (beads) with different sizes and fluorescent
intensities and each bead binds a specific protein (similar
to the ELISA technique). Each CBA assay includes seven
principal steps: preparation of beads, preparation of Phy-
coerythrin reagent, setting standard curve, preparation of
samples, cytometer calibration, acquisition of samples, and
file analysis. We analyzed four phosphorylated, and their
respective native, proteins: AKT, p-ATK, P38, p-P38, MEK,
p-MEK, STAT1, and p-STAT1. These proteins represent
the most important pathways downstream of the JAK2
signaling pathway. Protein concentrations were analyzed
using concentration ratios of phosphoproteins normalized
with non-phosphoproteins and total protein.
Table 2 Clinical and laboratory features of myeloproliferative neoplasm (MPN) patients used for
immunohistochemistry (IHC)
Clinical and laboratory variables PV ET JAK2 + ET JAK2 -
Patients 12 10 13
Gender (M/F) 6/12 2/8 7/6
Age at diagnosisa 66 (37–72) 55 (33–77) 44 (25–62)
Splenomegaly at diagnosis 2/12 5/10 1/13
Hepatomegaly at diagnosis 2/12 2/10 1/13
Hemoglobin (g/100 mL) at diagnosisa 20.05 (17.5-22.5) 15.2 (12.7-16.2) 14.15 (12.1-16.3)
Hematocrit at diagnosisa 58 (51.1-66.4) 45.2 (38.3-48.3) 41.15 (35.6-48.9)
WBC (x109/L) at diagnosisa 11.1 (5.91-14.7) 8.125 (5.96-11.4) 11.6 (5.24-15.3)
Platelets (x109/L) at diagnosisa 436.5 (305–1328) 680 (551–1210) 875 (514–3500)
Increased LDH at diagnosis 4/12 0/10 2/13
Thrombotic events at diagnosis 2/12 1/10 2/13
Hemorrhagic events at diagnosis 0/12 0/10 0/13
Thrombotic events after diagnosis 1/12 1/10 2/13
Hemorrhagic events after diagnosis 1/12 0/10 1/13
Disease duration (in months) 87 (24–138) 148.5 (46–333) 87 (0–256)
Treatment duration (in months)a 83 (0–138) 108 (0–330) 87 (0–256)
Response to treatment 8/12 8/10 8/13
PV, polycythemia vera; ET, essential thrombocythemia; HU, hydroxyurea; M, male; F, female; WBC, white blood cells, LDH, lactate dehydrogenase aMedian value
(range) is reported.
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V617F EPOR cell lines culture
To confirm the above CBA results, we analyzed JAK-
STAT and MAPK activation after KNK437 treatment, a
specific pharmacological HSP70 inhibitor, in HEL and
Ba/F3 JAK2 V617F EPOR cell lines that were kindly
transferred by Dr A. Quintas-Cardama for MD Anderson,
and cultured as previously described [25]. We used these
cell lines as MPN model due to its JAK2 mutational sta-
tus. HEL cells were obtained from the DSMZ collection
(cells were obtained on 01/08/2008; JAK2 V617F mutation
status was tested by QRT-PCR on 01/06/2012, finding
JAK2 V617F mutation in homocigosis) and cultured in
RPMI-1640 medium containing 10% fetal calf serum, with
L-glutamine and NaHCO3 in a humidified 5% CO2 atmos-
phere. For the inhibition assay, subconfluent cells in
9.5 cm2 wells (P6) were treated with KNK437 (50 μM) for
24 hours. Results were analyzed with the trypan blue via-
bility test. Cells were washed twice in PBS and protein
was extracted with the Cytobuster protein extraction re-
agent (Novagen, EMD Bioscences Inc., Madision, WI).
The protein concentration was determined using a non-
interfering assay (RC-DC Protein Assay Kit; BIO-RAD,
NY, USA) and Western Blot was performed using rabbit
anti-actin primary antibody (protein control), anti-p-MEK
(ser217/221), anti-ERK, anti-p-ERK (thr202/tyr204), anti-
p-P38 (thr180/tyr182), anti-JAK2, anti-p-JAK2 (tyr1007/1008) , anti-STAT5, anti-p-STAT5 (ser456) (Cell signaling,
Beverly, MA, USA), and mouse anti-HSP90 and anti-
HSP70 (R&D, Minneapolis, MN, USA). The membranes
were then incubated with the respective secondary anti-
bodies for 1 h and antigens were detected by using the
ECL Advance Western Blotting Detection Kit (GE Health-
care, Piscataway, NJ, USA).
HSP70 interference on HEL cell line culture
In order to confirm the specificity of KNK437 over HSP70,
we analyze the effect of the interference on HSP70 mol-
ecule through a specific siRNA. HEL cell line was trans-
fected using the Amansa Electronucleofector 2b and Cell
Line Nucleofector kit V (Lonza, NJ, USA). Anti HSP70
siRNA Trilencer 27 was acquired from Origene (Rockvile,
MD, USA). Cells were incubated 8 h. Pmax gfp (Lonza
USA, NJ) was used as a fluorescent control, showing a
transfection efficacy greater than 80%.
Statistical and bioinformatic analysis
The 2D-DIGE results were analyzed with a Batch Proces-
sor of DeCyderv7.0 with the following parameters: 1) For
PV vs. ET analysis an increase or diminution of 1.5 times
and t-test P < 0.05 was considered significant. In addition,
the spot should be found in all extracted images. 2) For
ET vs. healthy donors, and PV vs. healthy donors, parame-
ters were an increase or diminution of 3 times, and t-test
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found compared to PV vs ET analysis, in order to select a
small number of spots for further studies.
Mass spectrometry results were analyzed with Mascot
software.
Western blot data images were analyzed using ImageJ
(National Institute of Health, USA) with gel tool. Numerical
data were processed with the Mann–Whitney test (SPSS,
SPSS Inc., Chicago, Illinois, USA).
Flow cytometry was run in Cell Quest software, and
data were analyzed with the Summit 4.3 program. Ex-
tracted numerical data were analyzed statistically with the
Mann–Whitney test (SPSS, SPSS Inc., Chicago, Illinois,
USA).
IHC and culture data were also analyzed using the
Mann–Whitney test.
KNK437 Ic50 of BFU-E inhibition assays were calculated
using the GraphPathPrism 5.04 (GraphPath Software Inc.).
CBAs files were processed with FCAP Array™ (BD Bio-
sciences Europe, Oxford, UK), and data analyzed with
the Mann–Whitney test.
Statistical significance was considered when the P-
value was < 0.05.
Results
Identification of differentially expressed proteins using
Two-dimensional difference gel electrophoresis and
mass spectrometry
DIGE and MS were used to identify differences in the
whole cytosolic proteome between PV and ET groups.
Figure 2A, show three representative spots from the prote-
omic analyses of samples from ET and PV patients. We
found 112 spots representing proteins with differential ex-
pression between both diseases. Identification of the spots
yielded 65 proteins. Three proteins were especially inter-
esting in the context of our model and selected for further
studies by doing a literature search on their biological
function. These three differentially expressed proteins in-
cludes LTA4H, SERPINB1 and HSP70 (Figure 2A). Of
note, HSP70 is a chaperone related to GATA-1 and eryth-
roid differentiation. Most of the other spots corresponded
to a large group of proteins implicated in metabolic and
biochemical processes, for example, glycogen phosphoryl-
ase, pyruvate kinase, and lactotransferrin. Healthy donors
also showed differences when compared with PV samples.
There were 174 spots and 19 proteins identified (HSP70
included). Samples from controls and ET showed differ-
ences in 97 spots, and six proteins were identified. Most
of the proteins identified were implicated in metabolic
and biochemical pathways, similarly to those observed
when ET and PV were compared. A full list of the differ-
entially expressed proteins is summarized in Additional
file 1: Table S1, Additional file 2: Table S2 and Additional
file 3: Table S3.Validation of proteomic analysis by
immunohistochemistry in bone marrow
Bone marrow IHC analysis of HSP70, SERPINB1, and
LTA4H was performed to confirm and identify the ex-
pression pattern found by 2D-DIGE/MS. Twelve bone
marrow biopsies from PV patients, 10 ET JAK2 V617F
positive, 13 ET JAK2 V617F negative, and 11 controls
were studied. HSP70 was markedly over-expressed in PV
bone marrow (median of 80% positive granulocytes,
range 2-95%, SD 0.35%) vs. ET (median of 23% positive
granulocytes, range 1-95%, SD 34.25%) (Figure 2B-C). A
full list of the HSP70 expression sample per sample is
summarized in Additional file 4: Table S4.
SERPINB1 was expressed in the nucleus and cyto-
plasm of the granulocytes. We found a differential ex-
pression pattern between the bone marrow of controls
(median of 20% positive granulocytes, range 2-99%, SD
39.05%) and PV (median of 95% positive granulocytes,
range 65-99%, SD 16.72%), ET JAK2 V617F (median of
67% positive granulocytes, range 5-99%, SD 36.04%), and
ET JAK2 wild-type (median of 98% positive granulo-
cytes, range 3-98%, SD 38.31%).
LTA4H also was expressed in granulocytes and in a
small percent of the megakaryocytic lineages. It was
expressed in 90-100% of the bone marrow studied and
in 90-100% of the granulocytes, and no differences were
observed between the different groups (data not shown).HSP70 inhibition ex-vivo study; implication in
polycythemia vera erythroid differentiation
Inhibition of HSP70 with KNK437 showed similar re-
sults in primary BFU-E cultures, with and without EPO.
Bone marrow CD34+ cell cultures showed equivalent re-
sults to peripheral blood mononuclear cell cultures.
BFU-E cultures of CD34+ cells with KNK437 showed
a decrease of colony formation and erythroid precursor
viability. This KNK437-mediated decrease of viability
reached an IC50 of 20.05 μM in PV samples. Erythroid
precursor cell viability in cord blood samples and ET
patient cells was higher (IC50 = 38.87 μM) than in the
PV patients (Figure 3A-B). KNK437 also decreased cell
viability in the HEL and Ba/F3 JAK2 V617F cell lines
(Figure 3C). However, statistical significance among the
groups was not found.
Flow cytometry results of BFU-E colonies showed differ-
ences in apoptosis among the erythroid population (that ex-
press CD71) in untreated PV cultures (10% annexin
positive cells) vs. treated (KNK437, 50 μM) cultures (34%
annexin positive cells). However, the same differences were
not seen when treated ET samples (KNK437, 50 μM) (21%
annexin positive cells) were compared with untreated cells
(10% annexin positive cells). Figure 4A-B shows the flow
cytometry results for the CD34+ BFU-E cultures.
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Figure 2 Two-dimensional difference gel electrophoresis (2D-DIGE) analysis and IHC validation. (A) Representative spots from three
proteins from 2D-DIGE gels and intensity quantification with DeCyder software v7.0. three spots were identified as LTA4H, SERPINB1 and HSP70
(HSPA1A). These spots were over-expressed in polycythemia vera (PV) vs. essential thrombocythemia (ET) samples. (B) Representative images
according the median of HSP70 staining of granulocytes from bone marrow of PV, and ET. (C) Box-plot of percentage of HSP70 positive
granulocytes quantified from IHC.
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http://www.molecular-cancer.com/content/12/1/142CBA analysis showed an important decrease of phospho-
STAT1 in PV samples patients (ratio of pSTAT1 in PV
without treatment: 29.2; ratio of pSTAT1 in PV samples
with KNK437, 50 μM: 21.55), however, we found no sig-
nificant differences in phospho-STAT1 with and with-
out KNK437 treatment in ET patients. We define ratios
as concentration ratios of phosphoproteins normalized with
non-phosphoproteins as total protein numeric value. Add-
itionally, phospho-MEK showed under-expression after
KNK437 treatment, and this was more pronounced in sam-
ples from PV patients (ratio in PV without treatment: 63.17;
ratio in PV with KNK437, 50 μM: 23.58) vs. ET patients (ra-
tio in ET without treatment: 66.19; ratio in ET with
KNK437, 50 μM: 59.82). Moreover, the other MAPK
phospho-protein, phospho-p38, was differentially expressed
with and without KNK437 treatment in samples from PV
patients (ratio in PV without treatment: 7.30; ratio in PV
with KNK437, 50 μM: 4.18), but was unchanged in ETpatients. Phospho-AKT showed no decrease with treat-
ment. A full list of the proteins and phospho-proteins ex-
pression sample per sample is summarized in Additional
file 5: Table S5.
HSP70 inhibition in an ex-vivo cell line
To confirm the molecular mechanism of the HSP70 in-
hibitor in the JAK2/STAT and MAPK pathways, we per-
formed Western blot on HEL and Ba/F3 JAK2 V617F
cell lines proteomes, with and without KNK437 (10-50-
100 μM) treatment (Figure 3D). This showed a reduction
of the phospho-JAK2 and phospho-STAT5 protein with
treatment (Figure 3E and F), but no reduction of
phospho-ERK and phospho-p38. ImageJ quantification
confirmed these results and showed a 50% reduction in
the expression of phospho-JAK2 in the HEL cell line fol-
lowing treatment with KNK437. Additionally, HSP70,
HSP90 and detection by Western Blot showed a slight
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Figure 3 KNK437 inhibition assay of cell cultures. (A) Viability test results of KNK437 (10, 50 and 100 μM) inhibition assay of mononuclear
peripheral blood burst formation unit-erythroid (BFU-E) cultures, with and without EPO. (B) Viability test results of a KNK437 (50 and 100 μM)
inhibition assay of CD34+ bone marrow BFU-E cultures, with and without EPO. (C) Viability test results of KNK437 treatment (50 μM) on HEL and
Ba/F3 JAK2 V617F (BAF3MUT) cell lines. X axis: concentration (μM); Y axis: % of viability cells (viability test) or BFU-E (BFU-E cultures) (D) Molecular
effects of KNK437 in HEL cell line Western blot of HSP90, HSP70, p-JAK2 (decreased with KNK437 treatment), p-ERK and p-P38. Actin was used as
the housekeeping control. (E) Molecular effects of KNK437 in Ba/F3 cell line Western blot of JAK2, p-ERK, ERK, p-STAT5, STAT5 AND Actin,
(F) Western blot of HSP90, HSP70 , JAK2, STAT5 and p-STAT5. Expression levels of HSP70, JAK2 and p-STAT5 decreased after HSP70 siRNA
interference on HEL cell line. Actin was used as the housekeeping control.
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http://www.molecular-cancer.com/content/12/1/142decrease of HSP70 expression after KNK437 treatment, but
no significant difference in HSP90 expression in the HEL
cell line, with and without KNK437 treatment (Figure 3D).
KNK437 decreased the activation of JAK2 as well as its ex-
pression. This decrease in JAK2 expression resulted in the
inhibition of leading proliferative pathways related to
JAK2 (Figure 3E) GATA1 also showed no differential ex-
pression with the HSP70 inhibitor treatment (Additional
file 6: Figure S1). Similarly to the primary BFU-E, incuba-
tion with the HSP70 inhibitor KNK437 (50 μM) in HEL
and Ba/F3 JAK2 V617F caused a reduction of 20-50% in
the cell viability (Figure 3C).
In order to validate the KNK437 inhibition on HSP70,
and check the specificity of this treatment, additionalFigure 4 Flow cytometry of KNK437 inhibition assay of CD34+ cell cu
marrow of polycythemia vera (PV) and essential thrombocythemia (ET) sam
marker (y axis) and annexin V (x axis). (B) Box-plot of percentage of AnnexiHSP70 interference was performed with specific a siRNA
(Figure 3F). The results showed a proper interference, de-
creasing the protein levels of HSP70, but not HSP90. Be-
sides, HSP70 interference assay produces the decrease of
the expression of JAK2, and the inhibition of JAK-STAT
signaling due to the decrease of phospho-STAT5.
Discussion
Many authors believe in the possibility of other events
and/or genetic alterations ‘upstream’ of the JAK2 muta-
tion in MPN [26-32]. This opens new frontiers in the
pathogenesis of the disease and the phenotypic diver-
gence among the different MPNs must be studied to find
new defective molecules that may potentially be used forltures. (A) FCM results of BFU-E cultured cells from CD34+ bone
ples, with and without KNK437 treatment (50 μM), and with the CD71
n V positive CD34+ culture cells quantified by flow cytometry.
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new molecular targets has been an under-used strategy
in MNP. This may be due to several factors, namely the
difficultly in selecting the correct target cell populations
and their protein fractions, or the lack of a high-quality
protein extraction technique. Moreover, these approaches
can lead to a huge number of differentially expressed pro-
teins that can introduce confusion in the absence of a
proper analysis. These putative differences also need to be
confirmed with further, specific, single-protein analyses
such as IHC.
In overcoming those problems, 2D-DIGE approach
could represent an unexplored and efficient method to find
new molecular targets in hematology. We found molecular
divergences between PV and ET granulocyte proteins. With
2D-DIGE we found more than sixty differentially expressed
proteins when we compared samples from PV and ET pa-
tients. We selected three proteins for further studies due to
their biological importance: LTA4H, HSP70, and SER-
PINB1 (Figure 2A-B-C). The LTA4H differences were not
confirmed with IHC. SERPINB1, however, was differen-
tially expressed in the controls and all MPN groups. Al-
though the cohorts were small, we could suggest validation
of Gel 2D-DIGE technique results, above all HSP70 PV
over-expression. However with this data we could just val-
idate previous results with other methodology, neither the
use of few number of samples not encourage to use these
data to other aim. Based on these results, further studies
are needed to elucidate its importance as a MPN
biomarker.
We focused on HSP70 expression. Surprisingly, this pro-
tein was over-expressed in samples from PV patients com-
pared with ET and healthy donors, and this difference
between PV and ET was confirmed with IHC (Figure 2B).
This led us to investigate the effect of HSP70 inhibition
in an ex vivo model of MPN. We demonstrated that
KNK437, a HSP70 inhibitor, increased erythroid apoptosis
in cell cultures from PV patients (Figure 4A-B). This effect
could be mediated by JAK2 inhibition, given that a de-
creased phosphorylation was shown after KNK437 treat-
ment (Figure 3D). This was corroborated by the decrease
of phosphoSTAT1 through cytometric bead array results
and over Ba/F3 JAK2V617F cell line (Figure 3E). Addition-
ally, we performed siRNA HSP70 interference assay,
observing similar results to KNK437 treatment: an inhib-
ition of JAK-STAT signaling. Thus, the results support the
specificity of KNK437, demonstrating that the effect of
KNK437 is due to the specific inhibition of HSP70. But
more importantly, these observations confirm the role of
HSP70 in the pathogenesis of PV, and that it could play
a role as a new molecular target for the treatment of
this disease.
These data reflect the key implication of HSP70 in PV
disease, playing a key role in proliferation, differentiation,and survival of the erythroid lineage. Inactivation of the
JAK/STAT pathway by the HSP70 inhibitor may be the ex-
planation. In accordance with the putative importance of
HSP in the pathogenesis of JAK-STAT -related hematologi-
cal disorders, a recent study described the potential thera-
peutic use of PU-H71, a HSP90 inhibitor, in experimental
models of MPN, ET and PV [13]. This study described a
crosstalk between JAK2 and a HSP90-like molecule, since
HSP90 inhibition was able to decrease JAK2.
Unfortunately, the clinical efficacy of HSP90 inhibitors
has been generally disappointing. One possible reason for
this is that treatment of cancer cell lines with HSP90 inhibi-
tors generally leads to significant activation of HSF1 and
up-regulation of HSP70; indeed, up-regulation of HSP70 is
a key biomarker for the inhibition of HSP90. Interestingly,
however, it was discovered that HSP70 inhibition ‘alone’
effectively disrupts the HSP90 chaperone system [33].
In the this study, we showed that inhibition of HSP70 de-
creases JAK2 activation (Figure 3D, E and F). However, we
found no significant effect of HSP70 inhibition on HSP90.
In particular, HSP70 inhibition by KNK437 or siRNA led to
a decrease in JAK2 and STAT1 or STAT5 phosphorylation,
whereas HSP90 remained unaffected (Figure 3D and E).
HSP70 and HSP90 may exert parallel effects in JAK2 acti-
vation. Recent experimental data show that they may bind
to the HOP protein and thus form a HSP70-HOP-HSP90
In summary, we have demonstrated that HSP70 could
be implicated in the pathogenesis of PV by means of a
comprehensive translational model from the systematic
proteomic analysis of the cytosolic fractions of the granu-
locytes of PV patients, and we confirmed these results
with IHC. Eventual proof of concept of the importance of
HSP in this disease was achieved by inhibiting the prolifer-
ation/apoptotic ratio and the blockade of JAK/STAT acti-
vation in cultured PV patient cells, after incubating these
cells with the HSP inhibitor, KNK437 or siRNA. Given the
moderate effect of direct, target-designed JAK2 blockers
in MPN treatment, [34,35] HSP70 inhibitors, may present
a promising future therapeutic strategy for PV patients.Additional files
Additional file 1: Table S1. MALDI-TOF/TOF identification of proteins
with significant changes in expression levels in polycythemia vera (PV)
and essential thrombocythemia (ET) patients.
Additional file 2: Table S2. MALDI-TOF/TOF Identification of proteins
with significant changes in levels in ET patients.
Additional file 3: Table S3. MALDI-TOF/TOF Identification of proteins
with significant changes in levels in PV patients.
Additional file 4: Table S4. IHC patients list and HSPA1A % of positive
granulocytes.
Additional file 5: Table S5. CBA results sample per sample from BFU-E
cultures with treatment (KNK437 50 mcM) and without
treatment (control).
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HEL cell line with and without KNK437 treatment (50 mcM). Actin was
used as the housekeeping control.
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